drugset / Trial / NCT03224702
First-in-Human Trial of Anti-ADAMTS-5 Nanobody in Healthy Volunteers
RandomizedParallel-groupDouble-blindTreatment
Summary
This First-In-Human trial will be conducted in healthy male subjects to explore the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of single doses of M6495.
Timeline
- Start
- 2017-09-04
- Primary completion
- 2018-08-06
- Completion
- 2018-08-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | M6495 | Protein / enzyme biologic | — | Subcutaneous |
Indications
No indication recorded.